Consort 2010 flow diagram

<p>Consort 2010 flow diagram</p

Pooled vaccine efficacy by Cox regression for the studies in Kenya and Senegal.

<p>Pooled vaccine efficacy by Cox regression for the studies in Kenya and Senegal.</p

Local and systemic adverse event profiles for each vaccination, stratified by severity.

<p>Local and systemic adverse event profiles for each vaccination, stratified by severity.</p

Vaccine efficacy by Cox regression for any parasitaemia and parasitaemia >10 per ml

<p>Vaccine efficacy by Cox regression for any parasitaemia and parasitaemia >10 per ml</p

Vaccine immunogenicity.

<p>(A and B). Anti-TRAP IgG titres and IFN-γ ELISpot responses to TRAP peptide pools before and after vaccination. **** p<0.0001, Kruskall-Wallis with Dunn’s post-test; ^^^^ p<0.0001, 2-tailed Mann Whitney test. Lines represent geometric means. (C). Correlation between humoral and cellular immunogenicity for ME-TRAP vaccinees, 2-tailed Pearson’s test, n = 54. (D). Proportion of vaccinees with positive responses to TRAP peptide pools after boosting with MVA. Labels on x-axis refer to peptide pools described in <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0167951#pone.0167951.s003" target="_blank">S3 Table</a>. E. Epitope mapping of TRAP peptide TT1-10, 11–20 and 21–30 using cryopreserved PBMC. Each colour represents a different volunteer, n = 6. F. Neutralising antibody titres to the ChAd63 vector measured in Senegalese and UK volunteers, 2-tailed Mann-Whitney.</p

Baseline characteristics

<p>Baseline characteristics</p

Parasite density as measured by PCR for each trial.

<p>Each line represents an individual volunteer. P = PCR testing performed. During the PCR monitoring follow-up period, blood samples were tested by PCR three times a week from day 70 to day 95 and once per week from day 98 to day 119.</p

Kaplan-Meier plots of time to first infection.

<p>(A) First episode of PCR positivity at any threshold for the trial in Senegal. (B). Combined analysis of data from the Senegal and Kenya trials. (C). First episode of PCR positivity at >10 parasites per ml for the trial in Senegal. (D). Combined analysis of data from the Senegal and Kenya trials</p